艾司西酞普兰和氟西汀对抑郁症治疗的临床疗效和认知改善研究

Clinical efficacy and cognitive improvement of escitalopram and fluoxetine in the treatment of depression

ES评分 0

DOI
刊名
Journal of International Psychiatry
年,卷(期) 2020, 47(1)
作者
作者单位

河南省许昌市人民医院 ;

摘要
目的:研究艾司西酞普兰和氟西汀对抑郁症治疗的临床疗效和认知改善作用。方法:以2017年1月至2019年1月为时间段,选取我院收治的抑郁症患者60例,将其随机分为2组,每组患者30例。采用氟西汀治疗对照组,采用艾司西酞普兰治疗观察组。比较两组治疗前后HAMD、MoCA评分情况、临床疗效、生活质量以及不良反应。结果:在HAMD、MoCA评分上,治疗前观察组为(24.3±1.7)分、(14.3±2.5)分,对照组为(24.2±1.6)分、(14.3±2.6)分,二者无统计学差异(T=0.0287/0.0369,P=0.457/0.624);治疗后观察组为(7.1±0.3)分、(20.3±1.5)分,对照组为(10.5±0.8)分、(17.4±1.5)分,二者存在统计学差异(T=3.0144/4.0268,P=0.000)。在治疗有效率上,对照组总体为86.67%,观察组总体为63.33%,二者存在统计学差异(X2=6.2174,P=0.000)。在情感职能、生理、躯体、社会等功能评分上,观察组分别为(76.3±2.5)分、(77.8±2.4)分、(78.9±3.2)分、(76.4±2.8)分,对照组分别为(61.2±2.5)分、(60.4±2.3)分、(62.5±2.7)分、(64.5±2.9)分,二者存在统计学差异(T=3.2541/3.1574/3.5124/3.0029,P=0.000)。在不良反应方面,对照组发生率23.33%,观察组发生率6.67%,二者存在统计学差异(X2=7.0354,P=0.000)。结论:针对抑郁症患者采用艾司西酞普兰的疗效较氟西汀更显著,前者可快速改善患者抑郁症状和认知功能,且不良反应较少,安全性较高,还可提升患者生活质量,因此值得应用推广。
Abstract
Objective: To study the clinical efficacy and cognitive improvement of escitalopram and fluoxetine in the treatment of depression. Methods: From January 2017 to January 2019, 60 patients with depression were enrolled in our hospital. They were randomly divided into 2 groups, 30 patients in each group. The control group was treated with fluoxetine, and the observation group was treated with escitalopram. The HAMD and MoCA scores, clinical efficacy, quality of life, and adverse reactions were compared before and after treatment. RESULTS: In the HAMD and MoCA scores, the observation group was (24.3±1.7) points and (14.3±2.5) points, and the control group was (24.2±1.6) points and (14.3±2.6) points. The difference was (T=0.0287/0.0369, P=0.457/0.624); after treatment, the observation group was (7.1±0.3) points, (20.3±1.5) points, and the control group was (10.5±0.8) points, (17.4±1.5) points. There was a statistical difference between the two (T=3.0144/4.0268, P=0.000). In terms of treatment efficiency, the control group was 86.67% overall, and the observation group was 63.33% overall. There was a statistical difference between the two (X2=6.2174, P=0.000). In the emotional function, physiology, physical, social and other functional scores, the observation group was (76.3±2.5) points, (77.8±2.4) points, (78.9±3.2) points, (76.4±2.8) points, and the control group was (61.2±2.5) points, (60.4±2.3) points, (62.5±2.7) points, (64.5±2.9) points, there was statistical difference between them (T=3.2541/3.1574/3.5124/3.0029, P=0.000). In terms of adverse reactions, the incidence of the control group was 23.33%, and the incidence of the observation group was 6.67%. There was a statistical difference between the two (X2=7.0354, P=0.000). Conclusion: The efficacy of escitalopram in patients with depression is more significant than that of fluoxetine. The former can rapidly improve depressive symptoms and cognitive function, with fewer adverse reactions, higher safety, and improve the quality of life of patients. Therefore, it is worth applying for promotion.
关键词
抑郁症;艾司西酞普兰;氟西汀;临床疗效;认知改善
KeyWord
depression; escitalopram; fluoxetine; clinical efficacy; cognitive improvement
基金项目
页码 78-79
  • 参考文献
  • 相关文献
  • 引用本文

刘文杰*. 艾司西酞普兰和氟西汀对抑郁症治疗的临床疗效和认知改善研究 [J]. 国际精神病学杂志. 2020; 47; (1). 78 - 79.

  • 文献评论

相关学者

相关机构